× Home Projects Partners Special Events FAQs Contacts
ihi-logo

Efficacy and Safety of Artemether-Lumefantrine, Artesunate Amodiaquine and Dihydroartemisinin-Piperaquine for the treatment of uncomplicated Falciparum Malaria in mainland Tanzania

Principal Investigator: Muhidin Mahende

Project leader/ Coordinator: Abdunoor Mlokozi

Project Administrator: Priscilla Mlay

Funding Partner: Muhimbili University of Health and Allied Sciences (MUHAS)

Start date: April 1, 2019

End date: March 30, 2020

Efficacy and Safety of Artemether-Lumefantrine, Artesunate Amodiaquine and Dihydroartemisinin-Piperaquine for the treatment of uncomplicated Falciparum Malaria in mainland Tanzania

Efficacy and Safety of Artemether-Lumefantrine, Artesunate Amodiaquine and Dihydroartemisinin-Piperaquine for the treatment of uncomplicated Falciparum Malaria in mainland Tanzania

This is surveillance study that meant to evaluate the efficacy as well as safety of the current anti-malarial regimen used in Tanzania mainland. The study will use the national malarial control program 8 sentinel sites located in selected zones. Children attending health facilities in Mlimba-Kilombero and Ipinda-Kyela aging from 6 months to the 10 years will be enrolled in the study.

Those with positive malarial smears and adhere to study requirements will invited to participate in the study by receiving assigned treatment regimen (ALU), malarial smear slide and dry blood spots in filter papers will be collected on scheduled days for evaluation.

Participants will attend scheduled follow up visits to the facility as instructed which will take about 8 visits within 28 days. The study aims to be recruiting 88 participants in Ipinda-Kyela and Mlimba in Morogoro in every Round.#